Anderson Christopher D, Bowman Lyndsey J, Chapman William C
Washington University School of Medicine, Department of Surgery, St. Louis, MO 63110, USA.
Expert Opin Biol Ther. 2009 Jan;9(1):133-7. doi: 10.1517/14712590802588773.
The topical use of thrombin has a long history in surgery as an adjunct for achieving operative hemostasis. Until recently the majority of thrombin used topically was derived from bovine plasma. This preparation has been proven to be immunogenic and has led to safety concerns in recent years. Recombinant human thrombin (rhThrombin) has recently been developed as an alternative for topical use for surgical hemostasis.
To review the clinical safety and efficacy data relating to rhThrombin using bovine-derived thrombin as a comparative standard.
This review summaries recent literature regarding topical use of rhThrombin using bovine thrombin as the 'gold standard' for topical surgical hemostasis.
The data indicates that topical rhThrombin is as effective as bovine thrombin for hemostasis and significantly less immunogenic.
凝血酶的局部应用在外科手术中作为实现手术止血的辅助手段已有很长历史。直到最近，局部使用的大多数凝血酶都来源于牛血浆。这种制剂已被证明具有免疫原性，近年来引发了安全担忧。重组人凝血酶（rhThrombin）最近已被开发作为外科止血局部应用的替代品。
以牛源凝血酶作为对照标准，综述与rhThrombin相关的临床安全性和有效性数据。
本综述总结了近期关于以牛凝血酶作为局部外科止血“金标准”的rhThrombin局部应用的文献。
数据表明，局部应用rhThrombin在止血方面与牛凝血酶一样有效，且免疫原性显著更低。
